1001327-26-9

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 61296-22-8 5-bromothiazol-2-amine hydrobromide 

Downstream Products

• 1093121-21-1 C₂₈H₂₅N₅O₇S 
• 1093121-22-2 C₂₇H₂₄N₂O₈S₂ 
• 1093121-16-4 C₂₉H₂₁N₃O₈S₂ 
• 1093121-23-3 C₂₆H₂₃N₃O₈S₂ 
• 1093121-08-4 C₃₁H₃₁N₃O₉S₂ 
• 1093121-06-2 C₃₁H₃₁N₃O₈S₂ 
• 1093120-75-2 C₂₈H₂₆N₂O₉S₂ 
• 1093121-24-4 C₂₉H₂₆N₄O₇S 
• 1093120-82-1 C₂₃H₂₄N₂O₆S 
• 1328984-60-6 methyl 3-[2-[[2-(4-cyclopropylsulfonylphenyl)-2-(2,4-difluorophenoxy)acetyl]amino]thiazol-5-yl]oxybenzoate 
• 1093120-80-9 C₂₇H₂₄N₂O₉S₂ 
• 1093121-43-7 C₂₇H₂₅N₃O₈S₂ 
• 1093121-39-1 C₂₈H₂₆N₂O₈S₂ 
• 1093121-38-0 C₂₉H₂₇N₅O₇S 

Relevant academic research and scientific papers

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is aryl or heteroaryl; R2 is halogen, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R5 is as defined herein; Z is O, S, S(O), S(O)2, or NR5a; X is S, O, N, NR3, or CR3; Y is NCR4 or N4; R3, R4, and R5 are as defined herein; R8 is aryl or heteroaryl; R6 and R7 are independently H, halogen, or alkyl; m is 0 or 1; and n is 0 to 3, or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

1, 3 - DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS

Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is alkyl, aryl, arylalkyl, heteroaryl, or he